Company Description
Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.
It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer.
The company was founded in 2020 and is headquartered in Warren, New Jersey.
| Country | United States |
| Founded | 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Dr. Ryan H. Saadi M.D., M.P.H, M.P.H. |
Contact Details
Address: 15 Independence Boulevard, Suite 410 Warren, New Jersey 07059 United States | |
| Phone | 646-807-8832 |
| Website | tevogen.com |
Stock Details
| Ticker Symbol | TVGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001860871 |
| ISIN Number | US88165K1016 |
| Employer ID | 98-1597194 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ryan H. Saadi M.D., M.P.H, M.P.H. | Co-Founder, Chief Executive Officer and Chairman |
| Kirti Desai | Chief Financial Officer and Director |
| Stephen Chen M.B.A. | Chief Technical Officer |
| Dr. Neal Flomenberg M.D. | Chief Scientific Officer, Global Research & Development Lead and Chairman of Corporate Board |
| Mittul Mehta | Chief Information Officer and Head of Tevogen.ai |
| Tapan V. Shah | Head of Investor Relations and Corporate Development |
| Jeffrey Feike M.P.H. | Chief Patient Officer, Member of Innovation and Public Health Advisory Council & Director |
| Sadiq Khan | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 16, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| May 16, 2024 | 8-K | Current Report |
| May 2, 2024 | 8-K | Current Report |
| Apr 29, 2024 | 8-K/A | [Amend] Current report |
| Apr 29, 2024 | 10-K | Annual Report |
| Apr 26, 2024 | 8-K | Current Report |
| Apr 10, 2024 | 8-K/A | [Amend] Current report |
| Apr 2, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Apr 2, 2024 | 8-K | Current Report |
| Mar 21, 2024 | 8-K | Current Report |